Evidence map›Paper›PMID 34627626›Full record

ReviewVaccine2021

Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.

Neelam Mukherjee, Esther Julián, Jordi B Torrelles, Robert S Svatek

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Coating bacteria for anti-tumor therapy.Frontiers in bioengineering and biotechnology · 2022
    Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Neelam MukherjeeDepartment of Urology University of Texas Health San Antonio (UTHSA), San Antonio, TX, USA.
Esther JuliánDepartament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
Jordi B TorrellesPopulation Health Program, Texas Biomedical Research Institute, San Antonio, TX, USA. Electronic address: jtorrelles@txbiomed.org.
Robert S SvatekDepartment of Urology University of Texas Health San Antonio (UTHSA), San Antonio, TX, USA. Electronic address: Svatek@uthscsa.edu.
The University of Texas Health Science Center at San Antonio · USTexas Biomedical Research Institute · USUniversitat Autònoma de Barcelona · ES

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM113896 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CAVAZOS, JOSE E · 2018 to 2022
$1.1M
Improving immunotherapy in bladder cancer by targeting immune dysfunctionK23CA178204 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SVATEK, ROBERT SCOTT · 2014 to 2017
$674k
NCI NIH HHS K23 CA178204NCI NIH HHS P30 CA054174NIGMS NIH HHS T32 GM113896
6 · The paper itself

Abstract

The Mycobacterium bovis Bacillus Calmette et Guérin (BCG) vaccine was generated in 1921 with the efforts of a team of investigators, Albert Calmette and Camille Guérin, dedicated to the determination to develop a vaccine against active tuberculosis (TB) disease. Since then, BCG vaccination is used globally for protection against childhood and disseminated TB; however, its efficacy at protecting against pulmonary TB in adult and aging populations is highly variable. Due to the BCG generated immunity, this vaccine later proved to have an antitumor activity; though the standing mechanisms behind are still unclear. Recent studies indicate that both innate and adaptive cell responses may play an important role in BCG eradication and prevention of bladder cancer. Thus, cells such as natural killer (NK) cells, macrophages, dendritic cells, neutrophils but also MHC-restricted CD4 and CD8 T cells and γδ T cells may play an important role and can be one the main effectors in BCG therapy. Here, we discuss the role of BCG therapy in bladder cancer and other cancers, including current strategies and their impact on the generation and sustainability of protective antitumor immunity against bladder cancer.

Indexed as

Mycobacterium bovisTuberculosisUrinary Bladder NeoplasmsBCG VaccineCD8-Positive T-LymphocytesChildHumansBCG VaccineBCGBladder cancerMycobacterium bovisTreatment

Identifiers

PMID34627626
PMCPMC9056065
OpenAlexW3202157117

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.